Prolyl hydroxylase domain

From Proteopedia

Jump to: navigation, search

Human PHD2 catalytic domain complex with Fe+2 ion (orange), inhibitor and sulfate, 3ouh

3D Structures of prolyl hydroxylase domain

2y33 – hPHD2 + Zn + quinolin derivative – human
3ouh, 3oui, 5v18 - hPHD2 + Fe + inhibitor
4kbz - hPHD2 (mutant) + Fe + inhibitor
5a3u - hPHD2 + Mn + inhibitor
4jzr - hPHD2 + Ni + inhibitor
3ouj - hPHD2 + Fe + 2OG
5l9r - hPHD2 (mutant) + Mn + 2OG
3hqr, 5l9b - hPHD2 (mutant) + Mn + HIF 1 α C terminal + 2OG
5l9v, 5la9, 5las - hPHD2 (mutant) + Mn + HIF NODD domain + 2OG
3hqu - hPHD2 + Fe + HIF 1 α C terminal + quinolin derivative
2hbt, 2hbu, 2g19, 2g1m, [[2y34], 4bqi], 2y34 - hPHD2 + Fe + quinolin derivative
4bqw, 4bqx, 4bqy - hPHD2 + Mn + quinolin derivative
5lat, 5lb6, 5lbb, 5lbc, 5lbe, 5lbf, 4uwd - hPHD2 (mutant) + Mn + quinolin derivative
4h6j – hPHD Pasb domain (mutant) + aryl hydrocarbon nuclear translocator (mutant)
5v1b - hPHD1 + Fe + inhibitor

References

  1. Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp. 2006;272:15-25; discussion 25-36. PMID:16686427
  2. Rosen M D, Venkatesan H, Peltier H M, Bembenek S D, Kanelakis K C, Zhao L X, Leonard B E, Hocutt F M, Wu X, Palomino H L, Brondtetter T I, Haugh P V, Cagnon L, Yan W, Liotta L A, Young A, Mirzadegan T, Shankley N P, Barrett T D, Rabinowitz M H. Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues. ACS Medicinal Chemical Letters. 2010 Oct 5.


Created with the participation of Andrew Winslow.

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel, Joel L. Sussman

Personal tools